by EBSCO CAM Review Board


Related Terms

  • Arrhythmogenic Right Ventricular Cardiomyopathy
  • Dilated Cardiomyopathy
  • Hypertrophic Cardiomyopathy
  • Idiopathic Dilated Cardiomyopathy
  • Idiopathic Hypertrophic Cardiomyopathy
  • Idiopathic Restrictive Cardiomyopathy
  • Restrictive Cardiomyopathy

Principal Proposed Natural Treatments

  • None

Other Proposed Natural Treatments

Cardiomyopathy is a little understood condition in which the muscle tissue of the heart becomes diseased. There are several distinct forms of cardiomyopathy that may or may not be similar in origin. Medical treatment consists mainly of medications that attempt to compensate for the increasing failure of the heart to function properly. A heart transplant may ultimately be necessary.

Proposed Natural Treatments for Cardiomyopathy

Cardiomyopathy is certainly not a disease that you should treat yourself! For this reason, we deliberately do not discuss dosage or safety issues in this section, although general guidelines can be found in the articles on these substances.

Coenzyme Q 10

Preliminary evidence suggests that the naturally occurring substance coenzyme Q 10 (CoQ 10 ) might offer benefit in some forms of cardiomyopathy. 1,2,3

In a 6-year trial, 143 people with moderately severe cardiomyopathy were given CoQ 10 daily in addition to standard medical care. 4 The results showed a significant improvement in cardiac function (technically, ejection fraction) in 84% of the study participants. Most of them improved by several stages on a scale that measures the severity of heart failure (technically, NYHA class). Furthermore, a comparison with individuals on conventional therapy alone appeared to show a reduction in mortality.

This study was an open trial , meaning that participants knew that they were being treated, and such studies are not fully reliable. There have been a few double-blind, placebo-controlled trials of CoQ 10 in cardiomyopathy as well. One such trial followed 80 people with various forms of cardiomyopathy over a period of 3 years. 5 Of those treated with CoQ 10 , 89% improved significantly, but when the treatment was stopped, their heart function deteriorated.

No benefit was seen in another double-blind study, but it was a smaller and shorter trial and enrolled only people who had one particular type of cardiomyopathy (idiopathic dilated cardiomyopathy). 6

For more information on coenzyme Q 10 , including dosage and safety issues, see the full coenzyme Q 10 article.


A small amount of evidence indicates that the vitamin-like supplement carnitine may be useful in cardiomyopathy. 8,9 For more information on carnitine, including dosage and safety issues, see the full carnitine article.

Herbs and Supplements to Use Only with Caution

Various herbs and supplements may interact adversely with drugs used to treat Cardiomyopathy. For more information on these potential risks, see the individual drug article in the Drug Interactions section of this database.


REF1 Langsjoen H, Langsjoen P, Langsjoen P, et al. Usefulness of coenzyme Q 10 in clinical cardiology: a long-term study. Mol Aspects Med . 1994;15(suppl):S165–S175.

REF2 Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q 10 . Proc Natl Acad Sci USA . 1985;82:4240–4244.

REF3 Poggesi L, Galanti G, Comeglio M, et al. Effect of coenzyme Q 10 on left ventricular function in patients with dilative cardiomyopathy. Curr Ther Res . 1991;49:878–886.

REF4 Langsjoen PH, Langsjoen PH, Folkers K. A six-year clinical study of therapy of cardiomyopathy with coenzyme Q 10 . Int J Tissue React . 1990;12:169–171.

REF5 Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q 10 . Proc Natl Acad Sci USA . 1985;82:4240–4244.

REF6 Permanetter B, Rossy W, Klein G, et al. Ubiquinone (coenzyme Q 10 ) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur Heart J . 1992;13:1528–1533.

REF7 Spigset O. Reduced effect of warfarin caused by ubidecarenone [letter]. Lancet. 1994;344:1372–1373.

REF8 Winter S, Jue K, Prochazka J, et al. The role of L-carnitine in pediatric cardiomyopathy. J Child Neurol . 1995;10(suppl 2):S45–S51.

REF9 Pepine CJ. The therapeutic potential of carnitine in cardiovascular disorders. Clin Ther . 1991;13:2–21.

REF10 Bertelli A, Ronca G. Carnitine and coenzyme Q 10 : biochemical properties and functions, synergism and complementary action. Int J Tissue React . 1990;12:183–186.

Revision Information

  • Reviewer: EBSCO CAM Review Board
  • Review Date: 12/2015
  • Update Date: 12/15/2015